Bisphosphonates before denosumab may prevent postdenosumab BMD rebound effect

Results from an ongoing study of postmenopausal women who discontinue osteoporosis treatment with denosumab (Prolia) so far support the use of denosumab as a second-line therapy after a bisphosphonate, unless otherwise indicated, in order to reduce the loss of bone mineral density (BMD) after its discontinuation and also to support treatment to reduce bone turnover biomarkers as much as possible after stopping denosumab.

Видео Bisphosphonates before denosumab may prevent postdenosumab BMD rebound effect канала MDedge: news and insights for busy physicians